Stroke (CVA) or Transient Ischemic AttackI-MASNCT07084051
Improve Medication Adherence Among Stroke Survivors in Rural Kentucky
A study testing I-MAS in people with Stroke (CVA) or Transient Ischemic Attack, run by Hend Mansoor at 1 site in United States.
Trial summary
To test the feasibility and promise of a combined intervention provided by community health worker (CHW) in collaboration with pharmacy technician and pharmacist to improve hypertension and long-term stroke outcomes by identifying and reducing barriers to medication adherence among ischemic stroke survivors. Read more about this study
- Who is it for?
- Ages 30 to 90 years
- Conditions the study is for
- Stroke (CVA) or Transient Ischemic Attack
- What is being tested?
- I-MAS
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Jul 2025to 31 Dec 2025
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients with history of ischemic stroke or transient ischemic attack (TIA) in the past 2 years
- residing in a rural county in Kentucky
Who cannot join
- significant aphasia
- cognitive impairment
- a terminal illness
- other neurologic deficits that would impede from providing informed consent or meaningfully participate in the one-to-one sessions.
- a prior aneurysmal subarachnoid hemorrhage and or aneurysm, cerebral venous sinus thrombosis, vasculitis, blood clotting disorder due to genetic causes
- if the patient does not take any secondary preventative medications
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Intervention to Improve Medication Adherence Among Stroke Survivors in Rural Kentucky
To test the feasibility and promise of a combined intervention provided by community health worker (CHW) in collaboration with pharmacy technician and pharmacist to improve hypertension and long-term stroke outcomes by identifying and reducing barriers to medication adherence among ischemic stroke survivors. This collaborative intervention involves a self-management program including an educational session on practical strategies to improve hypertension control (i.e., appropriately taking medications, necessity of treatment, and consequences of not taking medicine, etc.), complemented by individually-tailored sessions to identify and address barriers to medication adherence.
- Being tested
- I-MAS
- Medical subject headings
- Stroke, Ischemic Attack, Transient
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
I-MASBehavioural
Also called Improve Medication Adherence Among Stroke Survivors
Participants will receive a one-to one session with the pharmacy technician that involves two parts; the first part include education on ischemic stroke and risk factors such as practical strategies to improve hypertension control (i.e., appropriately taking medications, necessity of treatment, and consequences of not taking medicine, etc., making healthier dietary choices, exercising regularly, smoking cessation, alcohol intake, and managing blood sugar. The second part involves an interview to collect information on socio-demographics, clinical factors, co-morbidities, medications, and medication adherence barriers. During the second part of the session, the pharmacy technician will identify barriers to medication adherence for secondary prevention of stroke medications including antihypertensives, antithrombotic agents, and statins. The pharmacist will collaborate with the pharmacy technician to develop an action plan to address medication adherence barriers
| Study group | Role | What they receive |
|---|---|---|
| Stroke Survivors | Experimental | self-management program with an an educational session and an individually-tailored session on medication adherence. Receives: Behavioral: I-MAS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Medication Adherence Questionnaire
Medication adherence is measured using a 12-item questionnaire that determines how often medications are missed. Scores range from 12 to 48 with lower scores indicating better adherence
Measured: Baseline and at 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2025
- Study start24 Jul 2025
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stroke (CVA) or Transient Ischemic AttackStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 4 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hend Mansoor
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD)
- Responsible party
- Sponsor-investigator, Hend Mansoor, University of Kentucky
- Investigators
- Hend Mansoor, PharmD, PhD, Principal investigator, University of Kentucky
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07084051
- Sponsor's protocol ID
- 101375
- Other IDs
- 1P50MD019476-01
- Acronym
- I-MAS
- Status last verified
- Jan 2026
- First submitted
- 16 Jul 2025
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No